We are live on ! Find out more
MTRI icon

Mentari Therapeutics, Inc. Common Stock

4 hedge funds and large institutions have $28.5K invested in Mentari Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

0.11% less ownership

Funds ownership: 0.53% → 0.42% (-0.11%)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$4.57K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$1.11K

Top Sellers

No sellers this quarter

MTRI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2025, worth a combined $28.5K — up 115% from $13.3K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new MTRI positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $4.57K.

  • 4 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2025, up from 3 in Q1 2025.
  • Funds reported $28.5K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2025, up 115% quarter-over-quarter.
  • 1 fund opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2025 and 0 closed out, a net change of +1 holder.
  • The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2025 was UBS Group, an estimated $4.57K added.

Based on aggregated 13F filings for Q2 2025.